GB201711785D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201711785D0
GB201711785D0 GBGB1711785.4A GB201711785A GB201711785D0 GB 201711785 D0 GB201711785 D0 GB 201711785D0 GB 201711785 A GB201711785 A GB 201711785A GB 201711785 D0 GB201711785 D0 GB 201711785D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1711785.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Priority to GBGB1711785.4A priority Critical patent/GB201711785D0/en
Publication of GB201711785D0 publication Critical patent/GB201711785D0/en
Priority to TW107125058A priority patent/TW201907952A/zh
Priority to MX2020000752A priority patent/MX2020000752A/es
Priority to ARP180102042 priority patent/AR112460A1/es
Priority to SG11202000390TA priority patent/SG11202000390TA/en
Priority to JP2020503018A priority patent/JP2020527594A/ja
Priority to BR112020001320-0A priority patent/BR112020001320A2/pt
Priority to EP18746656.0A priority patent/EP3655033A1/en
Priority to MA049627A priority patent/MA49627A/fr
Priority to KR1020207005030A priority patent/KR20200032162A/ko
Priority to PCT/EP2018/069768 priority patent/WO2019016371A1/en
Priority to CA3070264A priority patent/CA3070264A1/en
Priority to CN201880060959.0A priority patent/CN111132697A/zh
Priority to EA202090333A priority patent/EA202090333A1/ru
Priority to US16/632,195 priority patent/US20200231694A1/en
Priority to UY0001037815A priority patent/UY37815A/es
Priority to AU2018303241A priority patent/AU2018303241A1/en
Priority to PH12020550024A priority patent/PH12020550024A1/en
Priority to IL272096A priority patent/IL272096A/en
Priority to CL2020000175A priority patent/CL2020000175A1/es
Priority to ZA2020/00881A priority patent/ZA202000881B/en
Priority to CONC2020/0001792A priority patent/CO2020001792A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GBGB1711785.4A 2017-07-21 2017-07-21 Antibodies Ceased GB201711785D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
AU2018303241A AU2018303241A1 (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti BST-1 antibody and a cytidine analogue
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG
CN201880060959.0A CN111132697A (zh) 2017-07-21 2018-07-20 包含抗bst-1抗体和胞苷类似物的药物组合
ARP180102042 AR112460A1 (es) 2017-07-21 2018-07-20 Combinaciones farmacéuticas
SG11202000390TA SG11202000390TA (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
JP2020503018A JP2020527594A (ja) 2017-07-21 2018-07-20 抗ｂｓｔ−１抗体及びシチジン類似体を含む医薬組合せ
BR112020001320-0A BR112020001320A2 (pt) 2017-07-21 2018-07-20 combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
EP18746656.0A EP3655033A1 (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
MA049627A MA49627A (fr) 2017-07-21 2018-07-20 Associations pharmaceutiques comprenant un anticorps anti-bst-1 et un analogue de cytidine
KR1020207005030A KR20200032162A (ko) 2017-07-21 2018-07-20 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물
TW107125058A TW201907952A (zh) 2017-07-21 2018-07-20 醫藥組合
CA3070264A CA3070264A1 (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
MX2020000752A MX2020000752A (es) 2017-07-21 2018-07-20 Combinaciones farmaceuticas que comprenden un anticuerpo anti bst-1 y un analogo de citidina.
EA202090333A EA202090333A1 (ru) 2017-07-21 2018-07-20 Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина
US16/632,195 US20200231694A1 (en) 2017-07-21 2018-07-20 Pharmaceutical combinations comprising an anti-bst-1 antibody and a cytidine analogue
UY0001037815A UY37815A (es) 2017-07-21 2018-07-20 Combinación farmacéutica que comprende anticuerpos antibst1, kits que la comprenden, métodos relacionados y usos de las mismas
IL272096A IL272096A (en) 2017-07-21 2020-01-16 Pharmaceutical combinations consisting of an anti-BST1 antibody and a cytidine analog
PH12020550024A PH12020550024A1 (en) 2017-07-21 2020-01-16 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
CL2020000175A CL2020000175A1 (es) 2017-07-21 2020-01-20 Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.
ZA2020/00881A ZA202000881B (en) 2017-07-21 2020-02-11 Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
CONC2020/0001792A CO2020001792A2 (es) 2017-07-21 2020-02-18 Combinaciones farmacéuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies

Publications (1)

Publication Number Publication Date
GB201711785D0 true GB201711785D0 (en) 2017-09-06

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1711785.4A Ceased GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies

Country Status (22)

Country Link
US (1) US20200231694A1 (enExample)
EP (1) EP3655033A1 (enExample)
JP (1) JP2020527594A (enExample)
KR (1) KR20200032162A (enExample)
CN (1) CN111132697A (enExample)
AR (1) AR112460A1 (enExample)
AU (1) AU2018303241A1 (enExample)
BR (1) BR112020001320A2 (enExample)
CA (1) CA3070264A1 (enExample)
CL (1) CL2020000175A1 (enExample)
CO (1) CO2020001792A2 (enExample)
EA (1) EA202090333A1 (enExample)
GB (1) GB201711785D0 (enExample)
IL (1) IL272096A (enExample)
MA (1) MA49627A (enExample)
MX (1) MX2020000752A (enExample)
PH (1) PH12020550024A1 (enExample)
SG (1) SG11202000390TA (enExample)
TW (1) TW201907952A (enExample)
UY (1) UY37815A (enExample)
WO (1) WO2019016371A1 (enExample)
ZA (1) ZA202000881B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
NZ618503A (en) * 2011-06-28 2016-03-31 Oxford Biotherapeutics Ltd Antibodies to adp-ribosyl cyclase 2
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
EP4045083B1 (en) * 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia

Also Published As

Publication number Publication date
US20200231694A1 (en) 2020-07-23
ZA202000881B (en) 2021-08-25
EA202090333A1 (ru) 2020-05-06
CO2020001792A2 (es) 2020-07-31
MX2020000752A (es) 2020-08-17
CA3070264A1 (en) 2019-01-24
AR112460A1 (es) 2019-10-30
SG11202000390TA (en) 2020-02-27
TW201907952A (zh) 2019-03-01
KR20200032162A (ko) 2020-03-25
CN111132697A (zh) 2020-05-08
CL2020000175A1 (es) 2020-06-12
AU2018303241A1 (en) 2020-02-20
PH12020550024A1 (en) 2021-02-15
BR112020001320A2 (pt) 2020-08-11
UY37815A (es) 2019-02-28
MA49627A (fr) 2020-05-27
WO2019016371A1 (en) 2019-01-24
EP3655033A1 (en) 2020-05-27
IL272096A (en) 2020-03-31
JP2020527594A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL267797B1 (en) Anti-gpc3 antibody
SG11202000660QA (en) Anti-tigit antibodies
PL3625259T3 (pl) Przeciwciała anty-sirpalfa
ZA202002141B (en) Anti-transthyretin antibodies
GB201709808D0 (en) Antibodies
IL273393A (en) New epsilon anti-CD3 antibodies
GB201601073D0 (en) Antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201621439D0 (en) IL-11Ra Antibodies
GB201610044D0 (en) Antibodies
GB201616699D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201603291D0 (en) Antibodies
GB201720970D0 (en) Antibodies
IL271067A (en) Anti-trkb antibodies
IL273529A (en) Anti-PACAP antibody
PT3484921T (pt) Anticorpos anti-il-22r
GB201711785D0 (en) Antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies
GB201709592D0 (en) Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)